The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study

被引：4
|
作者：
van Soest, Robert
de Morree, Ellen
Shen, Liji
Tannock, Ian
Eisenberger, Mario A.
De Wit, Ronald
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[2] Sanofi, Malvern, PA USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.44
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
44
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study
    van Soest, Robert J.
    de Morree, Ellen S.
    Shen, Liji
    Tannock, Ian F.
    Eisenberger, Mario A.
    de Wit, Ronald
    EUROPEAN UROLOGY, 2014, 66 (02) : 330 - 336
  • [2] Do patients with locally advanced prostate cancer and high Gleason score as negative predictive marker benefit from radical prostatectomy?
    Kuefer, R
    Loeffler, M
    Rubin, MA
    Volkmer, B
    Hautmann, RE
    Gschwend, JE
    JOURNAL OF UROLOGY, 2002, 167 (04): : 173 - 173
  • [3] Predictive factors in the upgrading of Gleason score in prostate cancer patients
    Koh, Nan Jun
    Chia, Sing Joo
    Tan, Jing Yuan
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 : 69 - 69
  • [4] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
    Berthold, Dominik R.
    Pond, Gregory R.
    Soban, Freidele
    de Wit, Ronald
    Eisenberger, Mario
    Tannock, Ian F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) : 242 - 245
  • [5] Limitations of biopsy Gleason grade: Implications for counseling patients with biopsy Gleason score 6 prostate cancer
    Sved, PD
    Gomez, P
    Manoharan, M
    Kim, SS
    Soloway, MS
    JOURNAL OF UROLOGY, 2004, 172 (01): : 98 - 102
  • [6] W Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study
    Berthold, D. R.
    Pond, G.
    DeWit, R.
    Eisenberger, M.
    Tannock, I. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Predictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy
    Moon, Seung Jin
    Park, Sung Yul
    Lee, Tchun Yong
    KOREAN JOURNAL OF UROLOGY, 2010, 51 (10) : 677 - 682
  • [8] COMPARISON OF BIOCHEMICAL RELAPSE-FREE SURVIVAL BETWEEN PRIMARY GLEASON SCORE 3 AND PRIMARY GLEASON SCORE 4 FOR BIOPSY GLEASON SCORE 7 PROSTATE CANCER
    Burdick, Michael J.
    Reddy, Chandana A.
    Ulchaker, James
    Angermeier, Kenneth
    Altman, Andrew
    Chehade, Nabil
    Mahadevan, Arul
    Kupelian, Patrick A.
    Klein, Eric A.
    Ciezki, Jay P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (05): : 1439 - 1445
  • [9] PREDICTIVE FACTORS FOR LOCALLY ADVANCED PROSTATE CANCER IN PROSTATE CANCER PATIENTS WITH GLEASON SCORE 6 OR LOWER
    Ha, Hong Koo
    Ku, Ja Yoon
    Lee, Jeong Zoo
    Chung, Moon Kee
    Chung, Jae Min
    Kang, Dong Ii
    JOURNAL OF UROLOGY, 2013, 189 (04): : E607 - E607
  • [10] The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer
    Abedi, Amir Reza
    Basiri, Abbas
    Shakhssalim, Nasser
    Sadri, Ghazal
    Ahadi, Mahsa
    Hojjati, Seyyed Ali
    Sheykhzadeh, Samad
    Askarpour, Sajjad
    Ghiasy, Saleh
    UROLOGY JOURNAL, 2021, 18 (04) : 395 - 399
12345